Please login to the form below
Oesophageal cancer
This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
BeiGene announces positive phase 3 trial results for liver cancer treatment
There were more than 900, 000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma. ... Japan. Last month, Novartis announced positive results from a phase 3 trial showing tislelizumab plus
Latest news
-
Novartis announces positive phase 3 trial results for advanced oesophageal cancer
Novartis has announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) for patients with advanced oesophageal cancer, regardless of PD-L1 status. ... The treatment is currently
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
-
Merck’s Keytruda gains two more approvals in Japan
The second indication is in colorectal cancer, targeting unresectable, advanced or recurrent high microsatellite instability (MSI-H) colorectal cancer. ... In the US alone, it is indicated for cancers including melanoma, non-small cell lung cancer,
-
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer
Merck &Co’s – known as MSD outside the US and Canada – Keytruda has received an approval from the US Food and Drug Administration (FDA) for the treatment of advanced oesophageal cancer. ... status. “There have been few advances in improving
-
BMS aims for US approval of Opdivo combo in stomach cancer
The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or oesophageal adenocarcinoma (EAC). ... free survival (PFS) in patients with
More from news
Approximately 7 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Deal Watch March 2016
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
